1. Pink Sheet
  2. >>Advanced Technologies
  3. >>Cell & Gene Therapies

Pilot Phase Of Operation Warp Speed For Rare Diseases Beginning Soon

 
• By Derrick Gingery

US FDA’s biologics center intends to ask for volunteers to help demonstrate the concept, modeled on the COVID vaccine effort, which includes speedier communication with sponsors to expedite development of products for rare diseases.

Operation Warp Speed and flag
Concepts used for development of COVID-19 vaccines could be implemented to speed development of gene therapies for rare diseases. • Source: Shutterstock

A new enhanced communication program for cell and gene therapy sponsors developing products for rare diseases is nearing its pilot-stage launch.

The US Food and Drug Administration’s Center for Biologics Evaluation and Research wanted to use some of the lessons from Operation Warp Speed to help rare disease products reach the market sooner

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Cell & Gene Therapies

More from Advanced Technologies

Ryoncil Chronology: Three Review Cycles, Two CRLs, One Dispute Resolution Request

 
• By Sue Sutter

The Pink Sheet’s Drug Review Profile looks at the timeline for the clinical development and US FDA review of Mesoblast’s remestemcel for graft-versus-host disease.

Gene Therapy Sponsor INTERACT, Pre-IND Meeting Confusion Lingers Despite FDA Guidance

 
• By Sue Sutter

PhRMA questioned whether proof-of-concept studies are needed before an INTERACT meeting and said a draft guidance describing the timing of definitive toxicology studies creates confusion.

US FDA’s Makary Floats Vague ‘Plausible Mechanism’ Approval Pathway For Rare Diseases

 
• By Sarah Karlin-Smith

Ascertaining the novelty and benefits of Makary’s new drug approval idea – along with what it would take to implement it – requires more clarity on the types of studies he envisions being used to grant and confirm “plausible mechanism’ approvals.